Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 258

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 258
---
 the Prior Underwriter’s out -of -pocketexpenses with $0 remaining. In addition, we will pay a termination fee of $100,000 upon the consummation of the offering. Of the $1,000,000 (or up to $1,150,000 if the over -allotmentoption is exercised in full) payable to the Representative upon the closing of this offering, Benjamin Securities, Inc. will receive $200,000 as payment for services as a capital markets advisor in connection with this offering. We estimate that the total expenses of the offering payable by us, excluding the total underwriting discount will be approximately $900,000. If we do not complete our initial business combination within the time period required by our second amended and restated memorandum and articles of association, the underwriters have agreed that (i) they will forfeit any rights or claims to their deferred underwriting discounts and commissions, including any accrued interest thereon, then in the trust account, and (ii) that the deferred underwriters’ discounts and commissions will be included with the funds held in the trust account that will be available to fund the redemption of our public shares. Discretionary Accounts The underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority. Representative Shares We have agreed to issue to the Representative and/or its designees, 200,000 ordinary shares (or 230,000 ordinary shares if the underwriters’ over -allotmentoption is exercised in full) upon the consummation of this offering. The holders of the representative shares have agreed (i) that they will not transfer, assign or sell any such shares without our prior consent until the completion of our initial business combination, (ii) to waive their redemption rights (or right to participate in any tender offer) with respect to such shares in connection with the completion of our initial business combination and (iii) to waive their rights to liquidating distributions from the trust account with respect to such shares if we fail to complete our initial business combination within 15 months from the closing of this offering (or up to 21 months from the closing of this offering if we extend the period of time to consummate a business combination). The representative shares have been deemed compensation by FINRA and are therefore subject to a lock -upfor a period of 180 days immediately following the commencement of sales of this offering. Pursuant to FINRA Rule 5110(e)(1), these securities may not be sold